Replimune Group Inc (REPL)
Advanced Melanoma · registered primary completion 2030-01-01 · NCT06581406
Published 2026-09-02Market cap $1,460M8 sourced statements
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma · PHASE2,PHASE3 · n=280 · recruiting
What this sheet is scored on
callCash of $195M against operating outflow of $79M per quarter gives roughly 2.5 quarters of runway against a registered primary completion 13.4 quarters out. On these figures the company raises capital within four quarters.
Balance sheet
factManagement has concluded there is substantial doubt about the company's ability to continue as a going concern.
“ing expenses, working capital needs, and other corporate uses, we will be required to seek additional financing, and there can be no assurance that such financing will be available on acceptable terms, if at all. If we are unable to obtain additional capital, substantial doubt about our ability to continue as a going concern could arise again, and may adversely affect our business, results of operations and stock pri…”
Market
factNo approved product carries Advanced Melanoma on label.
Trial registry
factRegistered design for NCT06581406: randomized, open-label, 280 participants (estimated). Primary outcome: Overall Survival (OS). 1 further primary outcome(s) registered.
Ownership and proceedings
factA securities proceeding is disclosed in Legal Proceedings.
“proceedings arising in the ordinary course of business. The Company records a liability for such matters when it is probable that future losses will be incurred and that such losses can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. On July 24, 2025, a class action complaint alleging violations of the federal securities laws was filed against the Comp…”
Share count and dilution
fact94,219,634 shares outstanding against 111,538,097 if every outstanding option, warrant and convertible were exercised. In that case 15.5% of a gain in enterprise value would accrue to those holders rather than to current shareholders.
Regulatory
factDesignations disclosed: Breakthrough Therapy, Fast Track. These accelerate review and, for Orphan, confer exclusivity if approved; none is evidence of efficacy.
Pipeline
fact7 distinct molecules in 8 active company-sponsored trials; RP2 accounts for 4 of them at Phase 1/Phase 2/Phase 3.
Don't see a name? Request a sheet. Any US-listed biotech with a Phase 3 or a pending
FDA decision — it gets built the same way, from the filings.
This sheet is dated and will not be edited. When the registered primary completion passes, its outcome is recorded on the
scoreboard and a new dated sheet is published if the filings change materially.